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BACKGROUND. In patients with hereditary or constitutional chromosomal anoma-
lies, testicular carcinoma can develop sporadically or on the basis of an underlying
hereditary genetic defect. Greater knowledge of these genetic defects would pro-
vide more insight into the molecular pathways that lead to testicular carcinoma. To
the authors’ knowledge, little attention has been paid to date to the comorbid
occurrence of testicular carcinoma in patients with hereditary disorders or consti-
tutional chromosomal anomalies.
METHODS. The authors performed a review of the literature.
RESULTS. Twenty-five different hereditary disorders or constitutional chromo-
somal anomalies have been reported in patients who developed seminomatous or
nonseminomatous testicular carcinoma.
CONCLUSIONS. Although most of these malignancies were too rare to enable the
detection of statistically significant correlations between the chromosomal/hered-
itary disorder and the testicular tumor, it was striking that many of the patients had
also other urogenital abnormalities. Susceptibility to urogenital abnormalities
seems to disrupt normal urogenital differentiation and suggests a correlation with
testicular dysgenesis and, thus, also with testicular carcinoma. Other evidence of
causal involvement has been found in the field of tumor cytogenetics. Some of the
genes responsible for hereditary disorders have been mapped to regions that are of
interest in the development of sporadic testicular carcinoma. Molecular studies on
candidate genes will be required to provide definite answers. Completion of the
human gene map and the availability of advanced gene arrays and bioinformatics
are expected to greatly facilitate further exploration of the role of hereditary genetic
defects in testicular carcinoma. Cancer 2003;97:984 –92.
© 2003 American Cancer Society.
DOI 10.1002/cncr.11155
KEYWORDS: testicular carcinoma, testicular dysgenesis, hereditary, syndromic ab-
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A lthough testicular carcinoma (seminoma and nonseminoma) is arare disease, it is the most common form of malignant disease in
men between the ages of 20 – 40 years.1,2 The exact etiology of testic-
ular carcinoma remains unknown; however, over the years, various
risk factors have been identified, including factors with an assumed or
definite genetic basis (i.e., cryptorchidism, familial testicular carcino-
ma). Greater understanding of the molecular foundation of hereditary
tumor predisposition will not only facilitate the identification of men
who have an increased risk of testicular carcinoma but also will
provide more insight into the origination of nonhereditary forms of
testicular carcinoma. There are various indications of a genetic pre-
disposition for testicular carcinoma.3,4 Supporting arguments are the
presence of familial clustering and the radical differences in incidence
of this tumor. Recently, DNA linkage studies have indicated the exis-
tence of a gene on the X chromosome that, when mutated in the germ
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line, is associated with an increased risk for the devel-
opment of testicular carcinoma. Another argument is
the presence of testicular carcinoma in patients with a
hereditary abnormality or with a constitutional chro-
mosomal anomaly. Systematic research into the inci-
dence of testicular carcinoma in patients with these
disorders is scarce in the literature.5,6 The objectives of
the current study were to study disorders that have
been reported in combination with seminomatous
and nonseminomatous testicular carcinoma in the lit-
erature and to examine the extent to which our cur-
rent knowledge of the genetics and pathogenesis of
these disorders contributes to gaining a better under-
standing of the oncogenesis of testicular carcinoma.
MATERIALS AND METHODS
A literature search was made for articles in the English
language on seminomatous and/or nonseminomama-
tous testicular carcinoma that cooccurred with hered-
itary disorders or constitutional chromosomal anom-
alies. We also searched for articles on risk factors for
testicular carcinoma, because risk factors that have
been established in the normal population also may
form part of a genetic condition and (partly) may
explain testicular carcinoma in patients with those
conditions. The literature sources were PubMed
(www.ncbi.nlm.nih.gov/PubMed), McKusick’s on-line
catalogue of hereditary phenotypes (Online Mendelian
Inheritance in Man; www.ncbi.nlm.nih.gov/Omim)
and Familial Cancer Database 1.2 (found at http://
facd.uicc.org).7 The keywords were (combinations of)
testicular cancer, germ cell cancer, seminoma, non-
seminoma, congenital anomalies, syndromes, heredi-
tary, inherited, mendelian, genetic, and risk factors. For
an additional source, we used the references listed in
the articles that were found using above-described
method. We excluded all articles that were not written
in English and/or that described hereditary disorders
or constitutional chromosomal anomalies with testic-
ular carcinoma other than (non)seminoma.
RESULTS
Our literature search revealed 83 articles and a total of
25 hereditary disorders and constitutional chromo-
somal anomalies in combination with testicular carci-
noma (see Table 1). Table 2 presents a list of recog-
nized risk factors for testicular carcinoma that can
occur as part of a hereditary disorder or constitutional
chromosomal anomaly (e.g., we excluded exposure to
estrogens in utero). Column 4 in Table 1 shows which
risk factors for testicular carcinoma were present per
disorder in correspondence with the factors num-
bered in Table 2. Detection of statistically significant
correlations between the chromosomal/hereditary
disorder and the testicular tumor could not be per-
formed due to the rarity of these disorders.
DISCUSSION
The literature search revealed 25 different hereditary
disorders and constitutional chromosomal anomalies
that cooccurred with seminomatous or nonsemino-
matous testicular carcinoma. These cooccurrences
can be explained in two ways. They simply may be
coincidental, or they may result directly or indirectly,
possibly interacting with other endogenous or exoge-
nous risk factors, from the constitutional genetic de-
fect underlying the hereditary disorders/chromosomal
anomalies in question.
The majority of the hereditary conditions listed in
Table 1 are extremely rare; only a few dozen to 100
patients with such a congenital disorder have been
described. The combination of testicular carcinoma
and a hereditary condition often was described only in
one or a few case reports, never as the subject of
clinical epidemiologic research into large groups of
patients with a certain hereditary abnormality. More-
over, many publications on hereditary disorders were
limited to relatively young patients, which means that
complications in adulthood, such as testicular carci-
noma, have received little attention. This may have led
to under-reporting of testicular tumors in patients
with such disorders. Conversely, there may be a pub-
lication bias in view of the remarkable nature of the
cooccurrence. These possible causes for bias and the
small number of patients reported make it difficult to
provide statistical proof of a significant correlation
between having a certain hereditary disorder and the
development of testicular carcinoma, unless the risk
of a testicular malignancy is relatively high in certain
hereditary disorders. The so-called intersex disorders
(and, in particular, gonadal dysgenesis) are examples
of such disorders. It is possible that 30% of individuals
with gonadal dysgenesis or mixed gonadal dysgenesis
have an increased risk of developing gonadal neopla-
sia. These patients have been known to develop a
gonadoblastoma; this form of in situ germ cell tumor
has the ability to transform into an invasive germ cell
tumor (e.g., seminoma). It appears to be the presence
of Y chromosome material in a dysgenetic gonad that
predisposes to testicular tumor development.8 –10
Due to the fact that it is difficult to gain insight
into the etiology of testicular carcinoma in patients
with a hereditary disorder through an epidemiologic-
statistical approach, it is important to find other ways
to study the nature of these cooccurrences. A finding
that is worthy of attention in this respect is that many
of the conditions listed in Table 1 also involve urogen-
ital differentiation disorders, several of which are
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TABLE 1
Hereditary Disorders and Constitutional Chromosomal Anomalies in Combination with Reported Testicular Carcinoma (Alphabetical Order)











Adrenogenital syndrome 201910 AR CYP21 located at 6p21.3 1 — 57,58
Congenital adrenal hyperplasia
Ataxia teleangiectasia 208900 AR ATM located at 11q22.3 4 11 2 59
Lois–Bar syndrome
Congenital total hemihypertrophy 235000 AR, Spor, Impr — — — 60
Hemihyperplasia
Isolated hemihyperplasia
Down syndrome 190685 — Trisomie 21 1 21 1 61–66
Trisomie 21
Familial male-limited precocious puberty 176410, 152790 AD LCGR located at 2p21 4 — 67
Familial atypical multiple-mole
melanoma syndrome
Familial dysplastic nevus syndrome
1555600, 155601 AD CDKN2A/p16 located at 9p21,
CDK4 located at 12q14,
CMM1 located at 1p36
— 12 1 68–71
Hereditary persistence AFP 104150 AD AFP located at 4q11–q13 — 4 2 72–75
Kallmann syndrome 1 308700 XLR KAL1 located at Xp22.3 1, 2, 4 X 1 76
Klinefelter syndrome — XXY X, Y 2, 4 X 1, Y 2 52,77–85
Li–Fraumeni syndrome 151623, 114450 AD TP53 located at 17p13.1,
CHK2 located at 22q12.1
— — 20,21
Marfan 154700 AD 15q21.1 — — 6,86
Mixed gondal dysgenesis
45,X/46,XY gonadal dysgenesis
233420, 306100 — X, Y 1, 2 X 1, Y 2 10,52,87–
91
Neurofibromatosis type I 162200, 162220 AD NF1 located at 17q11.2 — — 92
Von Recklinghousen disease
Noonan syndrome 163950 AD PTPN11 located at 12q24.1 1, 2 12 1 93,94
Male turner syndrome
Pterygium Colli syndrome
Persistent mullerian duct syndrome 261550 AR AMH located at 19p13.3–p13.2,
AMHR2 gene located at
12q13
1, 2, 3, 4, 5 12 1 95–100
Prader—Willi syndrome
Prader–Labhart–Willi syndrome
176270 AD, Impr cgd(15q)/UPD(mat) located at
15q11–q13
1, 2, 4 — 101,102
Proteus syndrome 176920 Spor, AD? — — — 103
Encephalocraniocutaneous lipomatosis
Prune belly syndrome 100100 Spor?, AD?, AR? — 1, 2 — 104,105
Rubinstein–Taybi syndrome 180849 AD CREBBP located at 16p13.3 — — 106
Broad thumb-hallux syndrome




Supernumerary nipples, familial 163700 AD? Multifactorial? — — 107–109
Polythelia, familial
Testicular germ cell tumor, familial 300228 XL Xq27 1, 2, 3 X 1 4
Von Hippel–Lindau disease 193300 AD VHL located at 3p25–p26 — — 19
X-linked ichthyosis 308100 XLR, AD STS located at Xp22.32 1 X 1 110,111
Steroid sulfatase deficiency
OMIM: Online Mendelian Inheritance in Man; AD: autosomal dominant; AR: autosomal recessive; XL: X-linked; XLR: X-linked recessive; Spor: sporadic; Impr: imprinting; 2: under-representation; 1:
over-representation; ---: data unknown;; AFP: -fetoprotein; UPD(mat): uniparental (maternal) disomy.
a OMIM numbers are from McKusick’s on-line catalogue of hereditary phenotypes (found at: http://www3.ncbi.nlm.nih.gov/Omim/).
b A question mark means that the mode of inheritance is suggested in the literature but is inconclusive.
c The name of the gene and locus or only the locus of the gene if the gene has only been mapped but not cloned.
d Risk factor numbers correspond with the number shown in Table 2
e The tumorcytogenetic abnormalities shown are known (parts of) chromosomes that were identified as abnormal in cytogenetic studies on (non)seminomatous tumors in general.
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known to be recognized risk factors for testicular car-
cinoma in the general population (Table 2). An exam-
ple is the Russel–Silver dwarf syndrome; over 40% of
these patients have cryptorchidism, hypospadia, and
an early onset of puberty.11 Although there is no proof
that these recognized risk elements are direct causal
factors or solely epidemiologic markers of an as yet
unknown causal factor, it is conceivable that, partic-
ularly in conditions that involve urogenital differenti-
ation disorders, testicular carcinoma develops as a
further expression of such differentiation disorders.
Skakkebaek et al. developed a model that aims to
explain the correlation between these well-established
epidemiologic risk factors, genetic factors, and testic-
ular carcinoma (Fig. 1).12,13 Those authors assume that
the cause of testicular carcinoma lies in a condition
they refer to as testicular dysgenesis syndrome (TDS),
which is postulated to be caused by a range of envi-
ronmental and/or genetic defects that disrupt the em-
bryonal programming of gonadal development during
fetal life. In the Skakkebaek model, known risk factors,
such as testicular maldescent (cryptorchidism), infer-
tility, and hypospadias, do not cause testicular carci-
noma but, rather, result from TDS, as does testicular
carcinoma. The genes underlying the hereditary con-
ditions listed in Table 1 may cause TDS and subse-
quently may cause (indirectly) testicular carcinoma,
together with a range of associated urogenital anom-
alies. The Skakkebaek model takes into consideration
a variety of urogenital defects and their severity, in-
cluding testicular carcinoma in the absence of con-
genital urogenital anomalies. The type of genetic de-
fect may influence the severity of TDS and, thus, the
severity and type of any associated urogenital anom-
alies. Currently, it is not clear whether cryptorchidism
results from TDS, as the model postulates, or whether
cryptorchidism (also) directly causes testicular carci-
noma. The decreased risk of testicular carcinoma after
orchidopexia indicates a more direct role in neoplastic
development, although the data are conflicting, and it
remains to be seen whether the Skakkebaek model is
correct.14 –17
From a theoretical point of view, it cannot be
excluded that, in a number of patients with testicular
carcinoma, another pathway of tumor development
has occurred in which testicular carcinoma develops
in a normal, differentiated testis (i.e., in the absence of
TDS, for instance, as a result of mutations in tumor
suppressor and/or [proto]oncogenes). In the heredi-
tary disorders referred to as the human cancer syn-
dromes,18 these mutations are present in the germline;
therefore, these disorders are of special interest when
looking at testicular carcinoma predisposition. Testic-
ular carcinoma has been reported in three of these
hereditary disorders: the Li–Fraumeni syndrome, neu-
rofibromatosis type 1 (Recklinghausen disease), and
Von Hippel–Lindau disease. Von Hippel–Lindau dis-
ease features (clear cell) renal cell carcinoma and ep-
ididymis cystadenomas as frequent urogenital anom-
alies.19 However, only a single report has been
published on testicular carcinoma in Von Hippel–
Lindau disease. Furthermore neurofibromatosis type 1
has been described a number of times in combination
with (bilateral) testicular carcinoma. Hartley et al. and
Heimdal et al. even suggested that testicular carci-
noma may be a rare manifestation in the Li– Fraumeni
syndrome.20,21
When attempting to unravel the molecular steps
that lead to testicular carcinoma, the field of tumor
cytogenetics can be very helpful. Cytogenetic studies
on testicular carcinoma have demonstrated an in-
crease in chromosome 12p in invasive testicular car-
cinoma. In addition, complex rearrangements have
been found with increases and decreases of specific
chromosomal material: (parts of) chromosomes 4, 5,
TABLE 2
Recognized Rik Factors for Testicular Carcinoma that May Be Part of
Hereditary Disorders and Constitutional Chromosomal Anomalies
Risk factor References
1 Cryptorchidism 112–118
2 Subfertility (infertility) 112,119,120
3 Inguinal hernia requiring surgery 112,113,121,122
4 Hypogonadism 61
5 Hypospadias 113
6 Early age at puberty 112,120,123,124
FIGURE 1. The testicular dysgenesis syndrome. The asterisk indicates the
possibility that cryptorchidism (testicular maldescent) acts as a causal risk
factor (for details, see Discussion). CIS: carcinoma in situ. Modified frame from
Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syn-
drome: an increasingly common developmental disorder with environmental
aspects. Hum Reprod. 2001;16:972–978.
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11, 13, 18, and Y are under-represented, whereas
(parts of) chromosomes 7, 8, 12, 21, and X are over-
represented.22–25 The search for genes in these regions
that are responsible for testicular carcinoma, includ-
ing 12p, is still in its early stages, and it remains
unknown which of these genes also may carry germ-
line mutations.26 To date, linkage studies on these
regions have isolated only Xq27 as the locus for a gene
(TGCT1) that may be responsible for familial cluster-
ing of testicular carcinoma.4 It is not clear whether the
HLA regions harbor a hereditary testicular carcinoma
gene: The data are controversial.27–33
Table 1 shows whether the genetic defects associ-
ated with the hereditary conditions lie in chromo-
somal regions that appear to be of interest in cytoge-
netic studies on testicular carcinoma. If there are
correlations, then this may be another clue to a causal
relation between testicular carcinoma and the genetic
defect concerned. It is striking that, in the current
literature review, we found six hereditary conditions
with underlying gene defects/regions that lie on the X
chromosome (Table 1); in addition, cryptorchidism
has been described in association with these six he-
reditary disorders. These findings, in combination
with evidence concerning the Xq27 region, suggest
that the X chromosome plays a role in the etiology of
cryptorchidism, resulting in testicular carcinoma pre-
disposition whether or not it is according to the model
of testicular dysgenesis (Fig. 1).
If, on the grounds of tumor cytogenetics or other
considerations (e.g., the fact that a gene already is
known to play a role in other types of tumor), a gene
appears to play a candidate role in the oncogenesis of
testicular carcinoma, then further molecular studies
on tumors may help to determine whether their role is
more or less probable. Such research can involve
searching for somatic gene mutations, loss of het-
erozygosity (LOH) (loss of the normal allele in the
tumor), changes in methylation status, and gene ex-
pression with the aid of immunohistochemistry or, on
a large scale, by means of gene expression arrays.
Currently, such research has been performed only on
a very limited scale on genes that are responsible for
the hereditary conditions listed in Table 1. Kume et al.
recently described a patient with neurofibromatosis
type 1 and testicular carcinoma in whom no LOH of
the NF1 gene could be demonstrated.34 This makes it
less probable that the NF1 mutation played a role in
the pathogenesis of testicular carcinoma in this pa-
tient. Studies concerning somatic mutations of the
gene for Von Hippel–Lindau disease in patients with
sporadic gonadal tumors have not yet revealed any
mutations.35 Screening for the gene of the Li–Fraum-
eni syndrome (TP53) in testicular tumors failed to
demonstrate any pathogenic mutations, although
some missense mutations of unknown pathogenicity
have been observed.36 Gene expression studies have
suggested that another associated gene (CHK2) may
play a role in testicular carcinoma.37 Somatic muta-
tions of p16 (the gene mutated in the germline in a
proportion of families with familial dysplastic nevus
syndrome) have been observed in testicular carcino-
ma.38 The insulin growth factor-binding protein (IG-
FBP) 1 gene may be involved in Russell–Silver syn-
drome, and immunohistochemical studies have
suggested a role of this protein in testicular carcinoma
development.39,40 Mouse models with germline de-
fects in the above-mentioned genes also may have
provided clues to associated tumors, although the
spectrum of associated tumors may differ significantly
between mice and humans. No testicular tumors were
found in knock-out mice for TP53, NF1, p16, VHL, and
a range of other known tumor-suppressor genes.41
Based on data generated by research to date, we still
cannot draw any definite conclusions regarding the
role of the above-discussed germline mutations in
testicular oncogenesis.
Completion of the human gene map and the
availability of advanced gene arrays and bioinformat-
ics undoubtedly greatly will facilitate further explora-
tion of the role of hereditary gene defects in testicular
carcinoma. The first gene expression profiling studies
on testicular carcinoma that used large-scale gene
arrays (chips) have been published recently, and it can
be expected that more candidate genes will be found
through studies like these.42 It would be interesting to
include the genes that are associated with hereditary
disorders mentioned in Table 1 in these expression
arrays, because they may prove to be associated with
testicular carcinoma. The testicular dysgenesis model
has implications for interpreting the results of these
expression studies. It is conceivable that some of the
genes that are important in testicular dysgenesis and
(subsequent) neoplasia are expressed normally only in
a narrow time window during early gonadal develop-
ment. Therefore, those genes will not be expressed in
normal adult testicular tissue; and, if they act as a step
in tumor development through loss of action, then
gene expression studies comparing adult normal tes-
ticular tissue and testicular carcinoma tissue will not
display any differences in expression. Gene expression
studies on normal gonads or dysgenic gonads during
various stages of development (including animal mod-
els) may suggest additional genes to be included in
further screening research for mutations.43
The objective of this review was to summarize the
current knowledge about the hereditary predisposi-
tion of testicular carcinoma. In a last remark about the
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possible psychological, social, ethical, and economic
implications of the identification of men who are at
increased risk of hereditary carcinoma, we note that
the literature on individuals with a family history of
malignancy shows that issues such as medicalization,
stigmatization, coping with disease-related worry and
anxiety, greater sense of vulnerability, difficulty un-
derstanding statistical risks and risk perception, as-
pects of decision making, changes in family dynamics
and planning, and difficulties with health insurance
are related to the progress of genetic science.44 – 46
In summary, the identification of a hereditary pre-
disposition for testicular carcinoma is likely to con-
tribute to our understanding of the development of
the nonhereditary variety and help to identify men
with an increased risk of testicular carcinoma. We
present an overview of hereditary disorders and con-
stitutional chromosomal anomalies that have been
described in the literature in combination with testic-
ular carcinoma. Although, from an epidemiologic
point of view, there seems to be only a direct or
indirect correlation between testicular carcinoma in
mixed gonadal dysgenesis and Xq27-linked familial
testicular carcinoma, the presence of urogenital dif-
ferentiation disorders and data from tumor cytoge-
netic research, combined with the knowledge on gene
loci of the discussed hereditary disorders, suggest that
such a relation also may exist in other syndromes.
New techniques are rapidly becoming available that
will enable us to complete the human gene map and
investigate the possible role of large numbers of can-
didate genes in the development of testicular carci-
noma.
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